Health and economic impact of 20-valent pneumococcal conjugate vaccine for adults aged 66–84 years in Japan and Shiga prefecture
PCV20 is cost-effective compared with PPSV23 and no vaccination in adults aged 66-84 years, which could reduce the future healthcare burden in Japan.
Authors
- Fumihiko Kakuno
- Tomoyuki Suzuki (ORCID: https://orcid.org/0000-0002-9746-8325)
- Catriona Crossan
- Yoko Hirano (ORCID: https://orcid.org/0000-0003-2151-2083)
- Jeffrey Vietri (ORCID: https://orcid.org/0000-0002-5610-3098)
- Kazumasa Kamei (ORCID: https://orcid.org/0000-0001-7220-5142)
- Keita Miyata
- Makiko Kusama
- Camille Moyon
- Shuhei Ito (ORCID: https://orcid.org/0000-0003-0289-7766)
- Piotr Karwala
Institutions
- Pfizer (United States) (US)
- Biwako Gakuin University (JP)
- Shimane Prefectural Institute of Public Health and Environmental Sciences (JP)
- Shiga Prefectural Education Center (JP)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Pfizer (Japan) (JP)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2025-06-13
- DOI
- https://doi.org/10.1080/14737167.2025.2519755
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer Japan